Mylan to grow women's health care franchise through Jai Pharma acquisition

Mylan Laboratories Limited, a subsidiary of global pharmaceutical company Mylan, expanded its health care offerings for women Nov. 20 by acquiring Famy Care Limited's female health care businesses known as Jai Pharma.

The acquisition will enable Mylan to create a leading women's health care franchise using its own expansive global business and supply chain infrastructure in combination with Jai Pharma's broad range of women's care products, strong technical capabilities and hormone manufacturing. Jai Pharma's portfolio will enhance Mylan's current offerings in North America and strengthen its women's care line in India.

"The completion of this transaction is an important milestone as we continue to grow our global women's health care franchise and take another step in our mission to provide the world's 7 billion people access to high-quality medicine," Mylan CEO Heather Bresch said.

Bresch said Mylan will continue to grow its business through the use of its commercial platform in Europe, which has been greatly improved with its recent deal with Abbott Laboratories. Mylan acquired Abbott's non-U.S. developed markets specialty and branded generics business earlier this year.

Mylan will also further accelerate its growth by supporting Family Planning 2020, a global partnership that advocates for the rights of girls and women in making decisions regarding having children. The initiative aims to provide 120 million girls and women with access to contraceptives by the year 2020.